AEON Biopharma
AEON
AEON
21 hedge funds and large institutions have $20.5M invested in AEON Biopharma in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 13 reducing their positions, and 69 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
21
Holders Change
-64
Holders Change %
-75.29%
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
5
Increased
2
Reduced
13
Closed
69
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
1 |
SIM
Sandia Investment Management
Boston,
Massachusetts
|
+$1.32M |
2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$549K |
3 |
Walleye Capital
New York
|
+$162K |
4 |
CCM
CAAS Capital Management
New York
|
+$120K |
5 |
FTUS
Flow Traders U.S.
New York
|
+$108K |
Top Sellers
1 |
![]()
Marshall Wace
London,
United Kingdom
|
-$13.3M |
2 |
DKCM
Davidson Kempner Capital Management
New York
|
-$12.8M |
3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$12.6M |
4 |
ECP
Empyrean Capital Partners
Los Angeles,
California
|
-$12.2M |
5 |
D.E. Shaw & Co
New York
|
-$11.9M |